886 related articles for article (PubMed ID: 33493448)
1. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
[TBL] [Abstract][Full Text] [Related]
2. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.
McAuley DF; Cross LM; Hamid U; Gardner E; Elborn JS; Cullen KM; Dushianthan A; Grocott MP; Matthay MA; O'Kane CM
Lancet Respir Med; 2017 Jun; 5(6):484-491. PubMed ID: 28526233
[TBL] [Abstract][Full Text] [Related]
3. The CHARTER-Ireland trial: can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: a study protocol and statistical analysis plan for a randomised control trial.
Sheehan JR; Calpin P; Kernan M; Kelly C; Casey S; Murphy D; Alvarez-Iglesias A; Giacomini C; Cody C; Curley G; McGeary S; Hanley C; McNicholas B; van Haren F; Laffey JG; Cosgrave D
Trials; 2022 Sep; 23(1):774. PubMed ID: 36104785
[TBL] [Abstract][Full Text] [Related]
4. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.
Abraham E; Baughman R; Fletcher E; Heard S; Lamberti J; Levy H; Nelson L; Rumbak M; Steingrub J; Taylor J; Park YC; Hynds JM; Freitag J
Crit Care Med; 1999 Aug; 27(8):1478-85. PubMed ID: 10470753
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
Villar J; Ferrando C; Martínez D; Ambrós A; Muñoz T; Soler JA; Aguilar G; Alba F; González-Higueras E; Conesa LA; Martín-Rodríguez C; Díaz-Domínguez FJ; Serna-Grande P; Rivas R; Ferreres J; Belda J; Capilla L; Tallet A; Añón JM; Fernández RL; González-Martín JM;
Lancet Respir Med; 2020 Mar; 8(3):267-276. PubMed ID: 32043986
[TBL] [Abstract][Full Text] [Related]
6. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
[TBL] [Abstract][Full Text] [Related]
7. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome.
Gates S; Perkins GD; Lamb SE; Kelly C; Thickett DR; Young JD; McAuley DF; Snaith C; McCabe C; Hulme CT; Gao Smith F
Health Technol Assess; 2013 Sep; 17(38):v-vi, 1-87. PubMed ID: 24028755
[TBL] [Abstract][Full Text] [Related]
8. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study.
Suter PM; Domenighetti G; Schaller MD; Laverrière MC; Ritz R; Perret C
Chest; 1994 Jan; 105(1):190-4. PubMed ID: 8275731
[TBL] [Abstract][Full Text] [Related]
9. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial.
Kor DJ; Carter RE; Park PK; Festic E; Banner-Goodspeed VM; Hinds R; Talmor D; Gajic O; Ware LB; Gong MN;
JAMA; 2016 Jun; 315(22):2406-14. PubMed ID: 27179988
[TBL] [Abstract][Full Text] [Related]
10. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial.
Constantin JM; Jabaudon M; Lefrant JY; Jaber S; Quenot JP; Langeron O; Ferrandière M; Grelon F; Seguin P; Ichai C; Veber B; Souweine B; Uberti T; Lasocki S; Legay F; Leone M; Eisenmann N; Dahyot-Fizelier C; Dupont H; Asehnoune K; Sossou A; Chanques G; Muller L; Bazin JE; Monsel A; Borao L; Garcier JM; Rouby JJ; Pereira B; Futier E;
Lancet Respir Med; 2019 Oct; 7(10):870-880. PubMed ID: 31399381
[TBL] [Abstract][Full Text] [Related]
11. [Quality of results of therapy of acute respiratory failure : changes over a period of two decades].
Briegel I; Dolch M; Irlbeck M; Hauer D; Kaufmann I; Schelling G
Anaesthesist; 2013 Apr; 62(4):261-70. PubMed ID: 23558717
[TBL] [Abstract][Full Text] [Related]
12. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study.
Neto AS; Barbas CSV; Simonis FD; Artigas-Raventós A; Canet J; Determann RM; Anstey J; Hedenstierna G; Hemmes SNT; Hermans G; Hiesmayr M; Hollmann MW; Jaber S; Martin-Loeches I; Mills GH; Pearse RM; Putensen C; Schmid W; Severgnini P; Smith R; Treschan TA; Tschernko EM; Melo MFV; Wrigge H; de Abreu MG; Pelosi P; Schultz MJ; ;
Lancet Respir Med; 2016 Nov; 4(11):882-893. PubMed ID: 27717861
[TBL] [Abstract][Full Text] [Related]
14. Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trial.
Richard JC; Terzi N; Yonis H; Chorfa F; Wallet F; Dupuis C; Argaud L; Delannoy B; Thiery G; Pommier C; Abraham P; Muller M; Sigaud F; Rigault G; Joffredo E; Mezidi M; Souweine B; Baboi L; Serrier H; Rabilloud M; Bitker L;
Lancet Respir Med; 2023 Nov; 11(11):991-1002. PubMed ID: 37453445
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
16. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
Aman J; Duijvelaar E; Botros L; Kianzad A; Schippers JR; Smeele PJ; Azhang S; Bartelink IH; Bayoumy AA; Bet PM; Boersma W; Bonta PI; Boomars KAT; Bos LDJ; van Bragt JJMH; Braunstahl GJ; Celant LR; Eger KAB; Geelhoed JJM; van Glabbeek YLE; Grotjohan HP; Hagens LA; Happe CM; Hazes BD; Heunks LMA; van den Heuvel M; Hoefsloot W; Hoek RJA; Hoekstra R; Hofstee HMA; Juffermans NP; Kemper EM; Kos R; Kunst PWA; Lammers A; van der Lee I; van der Lee EL; Maitland-van der Zee AH; Mau Asam PFM; Mieras A; Muller M; Neefjes ECW; Nossent EJ; Oswald LMA; Overbeek MJ; Pamplona CC; Paternotte N; Pronk N; de Raaf MA; van Raaij BFM; Reijrink M; Schultz MJ; Serpa Neto A; Slob EMA; Smeenk FWJM; Smit MR; Smits AJ; Stalenhoef JE; Tuinman PR; Vanhove ALEM; Wessels JN; van Wezenbeek JCC; Vonk Noordegraaf A; de Man FS; Bogaard HJ
Lancet Respir Med; 2021 Sep; 9(9):957-968. PubMed ID: 34147142
[TBL] [Abstract][Full Text] [Related]
17. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Vlaar APJ; Witzenrath M; van Paassen P; Heunks LMA; Mourvillier B; de Bruin S; Lim EHT; Brouwer MC; Tuinman PR; Saraiva JFK; Marx G; Lobo SM; Boldo R; Simon-Campos JA; Cornet AD; Grebenyuk A; Engelbrecht JM; Mukansi M; Jorens PG; Zerbib R; Rückinger S; Pilz K; Guo R; van de Beek D; Riedemann NC;
Lancet Respir Med; 2022 Dec; 10(12):1137-1146. PubMed ID: 36087611
[TBL] [Abstract][Full Text] [Related]
18. Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).
Chacko B; Peter JV; Tharyan P; John G; Jeyaseelan L
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD008807. PubMed ID: 25586462
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
[TBL] [Abstract][Full Text] [Related]
20. Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial.
Krenn K; Lucas R; Croizé A; Boehme S; Klein KU; Hermann R; Markstaller K; Ullrich R
Crit Care; 2017 Jul; 21(1):194. PubMed ID: 28750677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
